Lila Feisee

• Strategic Planning and Execution for Expanding BIO’s Global Reach in emerging markets including India and Asia Pacific
• Influencing Global Regulatory Policy related to novel therapeutics by developing BIO’s policies in key markets and in multilateral forums and creating connections with local industry and key government officials in Asia Pacific and India to implement these policies.
• Represented BIO in Key Global Multilateral Forums: Representation on World Health Organization, International Council on Harmonization, Asia Pacific Economic Cooperation, etc. Attended trade shows and client meetings, promoting company brand and building rapport with prospects and partners.
• Responsible for addressing trade barriers to biotechnology: TTIP, TPP and in WTO. Coordinated internal team to include BIO regulatory and IP policies.
• Initiated budget project management to implement BIO global regulatory activities.
• Orchestrated public and stakeholder relations as public face of company in global regulatory matters.

Implement BIO’s Intellectual Property (IP) Advocacy: Executive responsibility for directing activities relating to intellectual property advocacy in Trade agreements, the WTO and WHO.

Board and Staff Committee Oversight: Direct report and management responsibility for board level committee and staff level committee on intellectual property at BIO.

Revenue Generation: Increased BIO’s member base and revenues by establishing and managing a flagship intellectual property conference for biotechnology and pharmaceutical companies that generates over $200,000.00 in revenues including sponsorships.

Alliance and Coalition Development: Responsible for the development of new alliances and coalitions on IP issues with academics, the US government and other like- minded organizations. These alliances helped BIO to meet its advocacy goals on healthcare, biologics regulation and patent reform.

Orchestrated public relations coverage and stakeholder relations as public face of BIO's global IP activities.

• Implement BIO’s Intellectual Property (IP) Advocacy: Executive responsibility for directing activities relating to intellectual property advocacy.
• Board and Staff Committee Oversight: Direct report and management responsibility for board level committee and staff level committee on intellectual property at BIO.
• Alliance and Coalition Development: Responsible for the development of new alliances and coalitions on IP issues with academics, the US government and other like- minded organizations.
• Created highly researched and articulate papers such as congressional testimonies, comments and arguments.

Responsible for the review, analysis and examination of biotechnology patent applications

• Supervised and managed the activities and work products of 20 patent examiners in the area of recombinant proteins, antibody engineering and methods of therapy.
• Directed recruitment and retention of over 40 employees.
• Trained, supervised and evaluated staff, coached improvement management skills.

Developed and implemented Patent Office policies on biotechnology

• Developed the US Government’s policies pertaining to the examination of biotechnology inventions, including patenting nucleic acids and living organism which are currently in practice today.
• Developed the USPTO’s position on patent pools and their role in avoiding patent thickets.
• Directed the development of training materials for USPTO.

• Directly responsible for the review, analysis and examination of biotechnology patent applications.

National Cancer Institute: National Heart, Lung and Blood Institute Directly responsible for developing methodologies for the identification of novel tumor antigens.

• Specifically, identified tumor antigens involved in Burkitt’s lymphoma for use in testing.
• Cloned and sequenced monoclonal antibodies and tumor antigens.
• Transformed cell lines with nucleic acids having specific properties for expression.
• Published articles in scientific publications.
• Documented test results using computerized and manual transcription methods.
• Oversaw shipment and reception of laboratory specimens, verifying proper safety precautions and handling methods.
• Documented changes during experiments, noting unexpected issues arising during research activities.

• Responsible for neonatal genetic testing for hemophilia and Beta Thalessemia and developing methodologies for the identification Factor VIII deficiency.
• Cloned and sequenced Factor VIII specific antigen.
• Expressed and characterized recombinant proteins.
• Located disease markers and outlined findings in thorough reports for clinicians.
• Analyzed bodily fluids with laboratory equipment and detected anomalies related to diseased states or acute injuries.
• Identified and resolved unexpected results, directing secondary testing measures or collection efforts.